Ocular Therapeutix (OCUL) Total Non-Current Liabilities (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Total Non-Current Liabilities of $140.4 million for Q2 2026, up 6.83% year-over-year from $131.4 million in Q2 2025, and up 1.07% on a QoQ basis from $138.9 million in Q1 2026.
Ocular Therapeutix (OCUL) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported Total Non-Current Liabilities for 11 years, with the latest figure at $140.4 million in Q2 2026.
- Total Non-Current Liabilities for Q2 2026 came in at $140.4 million, up 6.83% year-over-year; the trailing twelve-month figure through Jun 2026 was $140.4 million (up 6.83% YoY), and the FY2025 annual result was $139.8 million, up 8.12% from the prior year.
- Total Non-Current Liabilities advanced to $140.4 million in Q2 2026, from $138.9 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $140.4 million in Q2 2026 and troughed at $94.6 million in Q1 2022.
- A 5-year average of $120.6 million and a median of $125.0 million in 2024 frame the typical range for Total Non-Current Liabilities.
- The widest annual swing landed in 2023, when Total Non-Current Liabilities rose 29.53%; it then declined 5.08% in 2024.
- A 5-year view of Total Non-Current Liabilities shows it stood at $107.6 million in 2022, then grew by 21.74% to $130.9 million in 2023, then declined by 1.22% to $129.3 million in 2024, then rose by 8.12% to $139.8 million in 2025, then increased by 0.37% to $140.4 million in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $140.4 million in Q2 2026, $138.9 million in Q1 2026, and $139.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | 140.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 140.37 Mn |
| Mar 31, 2026 | 150.05 Mn |
| Dec 31, 2025 | 139.84 Mn |
| Sep 30, 2025 | 137.69 Mn |
| Jun 30, 2025 | 145.27 Mn |
| Mar 31, 2025 | 126.14 Mn |
| Dec 31, 2024 | 142.45 Mn |
| Sep 30, 2024 | 138.23 Mn |
| Jun 30, 2024 | 139.28 Mn |
| Mar 31, 2024 | 111.34 Mn |
| Dec 31, 2023 | 130.94 Mn |
| Sep 30, 2023 | 143.15 Mn |
| Jun 30, 2023 | 107.69 Mn |
| Mar 31, 2023 | 118.76 Mn |
| Dec 31, 2022 | 113.82 Mn |
| Sep 30, 2022 | 100.76 Mn |
| Jun 30, 2022 | 96.81 Mn |
| Mar 31, 2022 | 94.59 Mn |
| Dec 31, 2021 | 96.70 Mn |
| Sep 30, 2021 | 94.34 Mn |